We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Last week, Allergan announced that a strategic review of its operations had led to a decision to divest its women’s health and infectious diseases unit – in doing so it hoped that investors would respond well to a leaner business.